Neulogy Ventures

Neulogy Ventures

Venture Capital and Private Equity Principals

About us

We help entrepreneurs build global companies! We founded Neulogy Ventures to finance and develop talented entrepreneurs and help their companies succeed in the global market. Neulogy Ventures builds on our thorough knowledge of the local tech scene, our deep and wide network of mentors and advisors from Silicon Valley to Vienna, and years of realizing equity investment transactions as both investors and entrepreneurs. We know both sides of the early-stage investment world and offer our portfolio companies unique expertise based on our past experience as entrepreneurs, investors and transaction managers. Neulogy Ventures is the first ever Slovakia-based management company to run fully regulated seed and VC funds structured along the highest industry standards. We have a strong commitment to professional, transparent and hands-on approach to working with both our portfolio companies and our investors.

Website
http://www.neulogy.vc
Industry
Venture Capital and Private Equity Principals
Company size
2-10 employees
Headquarters
Bratislava
Type
Privately Held
Founded
2013

Locations

Employees at Neulogy Ventures

Updates

  • 🌟 Celebrating Innovation and Growth in Slovak Digital Health 🌟 Our portfolio company Diagnose.me has just acquired DNA ERA - a move that brings together remote radiology expertise with DNA-based health analysis. Together, they'll be offering a more complete platform for preventive and precision medicine. We backed Diagnose.me in their early days because we believed in their vision to make quality healthcare more accessible to everyone. This acquisition shows not only their continued growth but adds another great chapter to Slovakia's flourishing tech story. 👏 A big congratulations to both teams - we're truly excited to see what innovations this partnership will bring to digital healthcare. Welcome to the family Michaela and Jakub! #DigitalHealth #Innovation #Slovakia #HealthTech 🚀

    Veľké spájanie v slovenskom digitálnom zdravotníctve. Diagnose.me kúpilo startup DNA ERA

    Veľké spájanie v slovenskom digitálnom zdravotníctve. Diagnose.me kúpilo startup DNA ERA

    forbes.sk

  • The team at StratifAI is pushing the boundaries of computational pathology and we are proud to be part of their journey. Welcome to the family Omar, Firas, Daniel and Jakob!

    View organization page for StratifAI, graphic

    533 followers

    We're thrilled to announce that StratifAI has raised €1.5M in pre-seed funding led by Neulogy Ventures and MultiplexDX International, with participation from Debiopharm, Arve Capital and Christoph Haarburger 🚀 With our diverse team of computer scientists and medical doctors, StratifAI builds the next generation of AI-based biomarkers to improve cancer patient outcomes 🧬 A huge thank you to our amazing investors, mentors and early supporters who believe in our vision. This is only the beginning! Check out the full press release below 👇 https://lnkd.in/gZj5uabH #precisiononcology #biomarkers #AI #cancer

    StratifAI raises €1.5M in pre-seed funding to advance AI-based precision oncology

    StratifAI raises €1.5M in pre-seed funding to advance AI-based precision oncology

    https://stratifai.com

  • 🚨 Investment Alert! 🚨 We’re excited to announce our latest investment in a groundbreaking area of medical science—mRNA technology. You’ve likely heard about mRNA as a pivotal element in the global response to the COVID-19 pandemic. While still a relatively new field with many challenges, mRNA shows immense promise for applications beyond COVID-19 vaccines. One of the pioneers in this space is Professor Thomas Tuschl, head of the Laboratory of RNA Molecular Biology at Rockefeller University. His innovations have led to the founding of companies like Alnylam Pharmaceuticals and Ventus Therapeutics. Now, together with Eric Ekland and their team, Professor Tuschl is embarking on a new venture—meet Anvesana. Anvesana is developing therapeutics aimed at treating disorders caused by insufficient protein production. Think of it as a "light dimmer" that can enhance specific gene expression. Hundreds of rare genetic diseases stem from insufficient protein production, many of which have devastating effects and lack approved treatments. Anvesana is already making progress, with its first therapeutic focused on Parkinson’s Disease. We’re proud to support Anvesana on this journey, leading a $1.8 million pre-seed round, joined by Pathway to Cures, New York Ventures, MultiplexDX International, and several Slovak and U.S. angel investors. Read more about Professor Tuschl’s groundbreaking work in the article below ⬇

    How one scientist's fascination with RNA changed medicine forever - News

    How one scientist's fascination with RNA changed medicine forever - News

    rockefeller.edu

  • Welcome aboard Ignacio Sbampato! Great to see more and more corporate leaders switching sides to join fast growing tech startups!

    View organization page for Excalibur, graphic

    875 followers

    We have a new Chief Revenue Officer! Ignacio Sbampato, former Chief Business Officer at ESET! With a distinguished career spanning over more than 20 years in the Cybersecurity industry, Ignacio brings a wealth of experience, strategic vision, and proven leadership to the Excalibur team as it continues to grow and innovate in the Identity & Access Management industry. Before joining Excalibur, Ignacio Sbampato held the role of Chief Business Officer at ESET, where he led the commercial areas of the company in their journey to become one of the TOP 5 global Endpoint Security vendors and the largest by revenue from the European Union. Prior to that, Ignacio was responsible for the Latin American region for ESET, where he developed the market from zero, establishing the vendor as one of the TOP 3 in the region. "I am proud of joining a company like Excalibur, that has all the attributes to become a global leader in the Cybersecurity market. Excalibur is an outstanding example of the commitment to innovation that can be found in Europe, and I am humbled by the opportunity to become part of the company and contribute to write the next successful chapter in their story", said Ignacio Sbampato. Ivan Klimek, Founder and CEO of Excalibur, expressed enthusiasm about the new appointment, stating, "Having someone of the experience and caliber of Ignacio as our new Chief Revenue Officer is going to be instrumental to take our company to a completely new level. His proven track record in successfully developing cybersecurity commercial strategies around the world will allow us to continue growing at a fast pace to become a household name in our industry" As Chief Revenue Officer, Ignacio will be responsible for accelerating the global growth of Excalibur. He will also contribute to the overall company and product strategy, helping Excalibur to achieve continued success and leadership in the Privileged Access Management market and beyond.

    • Ignacio Sbampato is the new Chief Revenue Officer at Excalibur
  • 💥 Luigi's Box and Persoo.cz starting 2024 with a BANG! 💥 Our Christian Mandl shares his thoughts: Neulogy Ventures was amongst the first investors in Luigi's Box in 2017 and we have been impressed by the teams' ambitious plans and relentless execution under the leadership of Gejza Nagy. With this first acquisition of Persoo.cz, Luigi's Box boosts its growth which so far had been solely organic. We stand ready to further support the Company as it continues to expand. Amazing work Gejza and the whole Luigi's Box team! 👏

    View organization page for Luigi's Box, graphic

    2,787 followers

    🚀 As we enter the new year, we are excited to announce a significant business development proudly. We are delighted to confirm that Persoo.cz has officially joined the Luigi's Box group, aligning with our strategic vision and company values for the future. This merger results from extensive and collaborative efforts between our CEO Gejza Nagy, Pavel Pinkas, the CEO of Persoo, and our investors, marking a milestone in our company's journey. Our shared ambitions and strategic goals have facilitated a seamless and strategic alliance. Incorporating Persoo into our operations strengthens our market presence and broadens our expertise thanks to gaining new colleagues who are distinguished professionals in the e-commerce sector. We assure our new clientele from Persoo a smooth transition to Luigi's Box's integrated platforms.  As we embark on this new phase, Luigi's Box is poised with innovative solutions and collaborative prospects, signaling a significant step in enhancing the e-commerce landscape. 💪 Stay tuned for more exciting updates! Your support and engagement are vital to our continued success and growth, and we thank you for that. Read more about this exciting development here below ⬇️ https://lnkd.in/ePC6Dkrc. #ecommerce #acquisition #partnership #milestone

    Synergy of Czech-Slovak Leaders in Search Optimization

    Synergy of Czech-Slovak Leaders in Search Optimization

    https://www.luigisbox.com

  • 🌟 Year in Review: 2023 Investing Highlights 🌟 Our mission at Neulogy Ventures has always been to support visionary founders who are not only ambitious but are also actively pushing the boundaries in sectors that matter most to our future – such as climate, health, and digital technologies. 📈 While reflecting on the past year, we're proud to share some preliminary key metrics for 2023: - Total Capital Deployed: €7 million - Number of New Investments: 2 (Trustmatic + 1 -> stay tuned) - Follow-on Investments: 8 (Vectary, GroupSolver, Inc., GA Drilling, Piano, MATSUKO , Diagnose.me, RF elements s.r.o. and Voltia) - Exits: 1 (Trustmatic) These achievements are not just numbers; they're a testament to the disruptive potential our founders and their teams bring to the table. 🚀 We're committed to building on this momentum and looking forward to working on all the plans we have in store for 2024!

Similar pages